Esperion Therapeutis.Inc. buy Vassago1
Summary
This prediction ended on 28.09.19 with a price of €34.15. The BUY prediction by Vassago1 finished with a performance of 3.30%. Vassago1 has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Esperion Therapeutis.Inc. | -11.554% | -11.554% | 22.819% | -86.579% |
iShares Core DAX® | 1.665% | 0.362% | 17.556% | 15.301% |
iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% | 36.536% |
iShares Nikkei 225® | 2.620% | 1.174% | 17.273% | 10.880% |
iShares S&P 500 | -0.091% | -1.597% | 24.739% | 36.919% |
According to Vassago1 what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Cons
Comments by Vassago1 for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Stopped prediction by Vassago1 for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
30.06.24
30.06.25
06.07.24
Esperion Therapeutis.Inc.
19.07.23
19.07.24
22.07.23
Esperion Therapeutis.Inc.
13.10.21
13.10.22
15.10.21
Esperion Therapeutis.Inc.
13.01.21
07.02.21
Esperion Therapeutis.Inc.
02.09.19
16.09.19
16.09.19